These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 18396126)
1. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126 [TBL] [Abstract][Full Text] [Related]
2. Serum FGF23 levels in normal and disordered phosphorus homeostasis. Weber TJ; Liu S; Indridason OS; Quarles LD J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832 [TBL] [Abstract][Full Text] [Related]
3. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia. Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556 [TBL] [Abstract][Full Text] [Related]
4. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. Imel EA; Hui SL; Econs MJ J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222 [TBL] [Abstract][Full Text] [Related]
5. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316 [TBL] [Abstract][Full Text] [Related]
7. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782 [TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 and its receptors. Yu X; White KE Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372 [TBL] [Abstract][Full Text] [Related]
9. Regulation of phosphate homeostasis in infants, children, and adolescents, and the role of phosphatonins in this process. Garabedian M Curr Opin Pediatr; 2007 Aug; 19(4):488-91. PubMed ID: 17630616 [TBL] [Abstract][Full Text] [Related]
10. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Xia W; Meng X; Jiang Y; Li M; Xing X; Pang L; Wang O; Pei Y; Yu LY; Sun Y; Hu Y; Zhou X Calcif Tissue Int; 2007 Dec; 81(6):415-20. PubMed ID: 18046499 [TBL] [Abstract][Full Text] [Related]
11. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels]. de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927 [TBL] [Abstract][Full Text] [Related]
12. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Quarles LD Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601 [TBL] [Abstract][Full Text] [Related]
13. FGF23 and disorders of phosphate homeostasis. Yu X; White KE Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037 [TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740 [TBL] [Abstract][Full Text] [Related]
15. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Kinoshita Y; Fukumoto S Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780 [TBL] [Abstract][Full Text] [Related]
16. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269 [TBL] [Abstract][Full Text] [Related]